Prediction of vascular events in subjects with subclinical atherosclerosis and the metabolic syndrome: The role of markers of inflammation

International Angiology

Volumn 31, Issue 3, 2012, Pages 219-226

  Corrado, E ^a   Rizzo, M ^a   Aluigi, L ^b   Patti, A M ^a   Coppola, G ^a   Muratori, I ^a   Caccamo, G ^a   Balasus, F ^a   Novo, S ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b MAGGIORE HOSPITAL   (Italy)

Author keywords

Atherosclerosis; Carotid intima media thickness; Inflammation; Metabolic syndrome X

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRINOGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COLOR ULTRASOUND FLOWMETRY; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HUMAN; HYPERTENSION; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MORBIDITY; OBESITY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; RISK FACTOR; STROKE; TRANSIENT ISCHEMIC ATTACK; TRIACYLGLYCEROL BLOOD LEVEL; UNSTABLE ANGINA PECTORIS;

AGED; ATHEROSCLEROSIS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION; MALE; METABOLIC SYNDROME X; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 84864759592     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. World Health Organization: Definition, Diagnosis, and Classification of Diabetes Mellitus and its Complications: Report of a WHO Consultation. Geneva, World Health Org., 1999
2. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999;16:442-3.
3. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-21.
4. Einhorn D, Reaven GM, Cobin RH, Ford E, Ganda OP, Handelsman Y et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 2003;9:237-52.
5. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr., Lenfant C; American Heart Association; National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109:433-8.
6. International Diabetes Federation. Worldwide definition of the metabolic syndrome [Internet]. Available at: http://www.idf.org/webdata/d3ocs/ IDF_Metasyndrome_definition.pdf [cited 2012, Mar 30].
7. Kahn R, Buse J, Ferrannini E, Stern M; American Diabetes Association; European Association for the Study of Diabetes. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005;28:2289-304.
8. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA et al. American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-52.
9. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-9.
10. Malik S, Wong ND, Franklin SS, Kamath TV, L'Italien GJ, Pio JR et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004;110:1245-50.
11. Rundek T, White H, Boden-Albala B, Jin Z, Elkind MS, Sacco RL. The metabolic syndrome and subclinical carotid atherosclerosis: the Northern Manhattan Study. J Cardiometab Syndr 2007; 2:24-9.
12. Burke GL, Evans GW, Riley WA, Sharrett AR, Howard G, Barnes RW et al. Arterial wall thickness is associated with prevalent cardiovascular disease in middle-aged adults. The Atherosclerosis Risk in Communities (ARIC) Study. Stroke 1995;26:386-91
13. Bots ML, Moons KG, Hollander M, Hoffman A, Koudstaal PJ, Grobbee DE et al. Is carotid intima-media thickness useful in cardiovascular disease risk assessment? The Rotterdam Study. Circulation 1997;96:1432-7.
14. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999;340:14-22.
15. Corrado E, Rizzo M, Tantillo R, Muratori I, Bonura F, Vitale G et al. Markers of inflammation and infection influence the outcome of patients with baseline asymptomatic carotid lesions:a 5 years follow-up study. Stroke 2006;37:482-6.
16. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial Hypertension. J Hypertens 2003;21:1011-53.
17. Murata M, Ide T. Determination of cholesterol in subnanomolar quantities in biological fluids by high-performance liquid chromatography. J Chromatogr 1992;579:329-33.
18. Montagne P, Laroche P, Cuilliere ML, Varcin P, Duheille J. Microparticle-enhanced nephelometric immunoassay for human C-reactive protein. J Clin Lab Anal 1992;1:24-9.
19. Myers G.L., Rifai N, Tracy R, Roberts W.L, Alexander R.W, Biasucci L et al. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease Application to Clinical and Public Health Practice Report From the Laboratory Science Discussion Group. Circulation 2004;110:577-8.
20. Von Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957;17:231-7.
21. Imperatore G, Riccardi G, Iovine C, Rivallese A, Vaccaro O. Plasma fibrinogen:a new factor of the metabolic syndrome. A population-based study. Diabetes Care 1998;21:649-54.
22. Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R. Intimal plus medial thickness of the arterial wall. A direct measurement with ultrasound imaging. Circulation 1986;74:1399-406.
23. Bard RL, Kalsi H, Rubenfire MD, Brook RD. Effect of carotid atherosclerosis screening on risk stratification during primary cardiovascular disease prevention. Am J Cardiol 2004;93:1030-2.
24. Anuurad E, Tracy RP, Pearson TA, Beckett L, Berglund L. Comparison of C-reactive protein and metabolic syndrome as cardiovascular risk factors in African-Americans and European-Americans. Am J Cardiol 2009;103:523-7.
25. Pasceri V, Chang J, Willerson JT, Yeh ETH. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000;102:2165-8.
26. Blackburn R, Giral P, Bruckert E, André JM, Gonbert S, Bernard M et al. Elevated C-reactive protein constitutes an independent predictor of advanced carotid plaques in dyslipidemic subjects. Arterioscler Thromb Vasc Biol 2001;21:1962-8.
27. Folsom AR, Aleksic N, Catellier D, Folsom AR, Aleksic N, Catellier D. C-reactive protein and incident coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J 2002;144:233-8.
28. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998;97:2007-201.
29. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001;103:1813-8.
30. Albert MA, Danielson E, Rifai N, Ridker PM; PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE):a randomized trial and cohort study. JAMA 2001;286:64-70.
31. Jialal D, Stein D, Balis D, Grundy S, Adams-Huet B, Devaraj S. Effect of Hydroxymethyl Glutaryl Coenzyme A Reductase Inhibitor Therapy on High Sensitive C - reactive protein Levels. Circulation 2001;103:1933-5.
32. Ridker P, Rifai N, Pfeffer M, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999;100:230-5.
33. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J et al. Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005;352:29-38.
34. Li JJ, Ren Y, Chen KJ, Yeung AC, Xu B, Ruan XM, Yang YJ et al. Impact of C-reactive protein on in-stent restenosis:a meta-analysis. Tex Heart Inst J 2010;37:49-57.
35. He LP, Tang XY, Ling WH, Chen WQ, Chen YM. Early C-reactive protein in the prediction of long-term outcomes after acute coronary syndromes:a meta-analysis of longitudinal studies. Heart 2010;96:339-46.
36. Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, Danesh J. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010;375:132-40.
37. C Reactive Protein Coronary Heart Disease Genetics Collaboration (CCGC), Wensley F, Gao P, Burgess S, Kaptoge S, Di Angelantonio E, Shah T et al. Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. BMJ 2011;342:d548.